Holen Sie sich die Stockscreener-App
50.96
6.05%
-3.28
Handel nachbörslich:
53.50
2.54
+4.98%
Schlusskurs vom Vortag:
$54.24
Offen:
$52.89
24-Stunden-Volumen:
1.90M
Relative Volume:
2.77
Marktkapitalisierung:
$3.33B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-8.5791
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-10.64%
1M Leistung:
-7.78%
6M Leistung:
+37.36%
1J Leistung:
+75.18%
1-Tages-Spanne:
$45.40
$52.89
1-Wochen-Bereich:
$45.40
$56.95
52-Wochen-Spanne:
$24.00
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
50.96 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Raymond James Financial Inc. - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Natixis Advisors LLC Invests $544,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics says Duchenne drug Translarna is no longer authorized in EU - MSN
Cibc World Markets Corp Acquires Shares of 7,127 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
PTC Therapeutics Faces EU Setback on Translarna - TipRanks
PTC Therapeutics says EC will not renew market authorization for muscle disorder drug - MarketScreener
PTC Therapeutics stock slips as EU ends Translarna nod (PTCT) - Seeking Alpha
PTC Therapeutics faces EC setback on Translarna in Europe - Investing.com
PTC Therapeutics (PTCT) Faces EU Setback for DMD Drug Translarna - GuruFocus
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder - Benzinga
PTC Therapeutics says EC not to renew market authorization for muscle disorder drug - MarketScreener
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe - Quantisnow
PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy - Marketscreener.com
PTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On Translarna - Nasdaq
PTC Therapeutics says European Commission will remove muscle disorder drug - MarketScreener
PTC Therapeutics Provides Regulatory Update On Translarna(TM) (Ataluren) In Europe - Marketscreener.com
PTC Therapeutics faces EC setback on Translarna in Europe By Investing.com - Investing.com Australia
Sector Gamma AS Purchases Shares of 65,250 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
A Shareholder alert for PTC Therapeutics, Inc was sent by Bronstein, Gewirtz and Grossman, LLC to Lead Class Action Lawsuit! - ACCESS Newswire
AlphaQuest LLC Has $49,000 Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighShould You Buy? - MarketBeat
First Week of May 16th Options Trading For PTC Therapeutics - Nasdaq
Leigh Syndrome Treatment Market Size in 7MM is expected to grow - openPR
Connor Clark & Lunn Investment Management Ltd. Sells 15,278 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Proficio Capital Partners LLC Takes $758,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Stephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Insider Sell Alert: Eric Pauwels Sells Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
Charles Schwab Investment Management Inc. Trims Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics reports progress in PKU treatment study By Investing.com - Investing.com Australia
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - Benzinga
PTC Therapeutics reports progress in PKU treatment study - Investing.com India
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JPMorgan Chase & Co. Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $78.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High After Analyst Upgrade - MarketBeat
PTC Therapeutics chief business officer sells $630,104 in stock - Investing.com India
PTC Therapeutics chief business officer sells $630,104 in stock By Investing.com - Investing.com UK
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Mark Elliott Boulding Sells 15,521 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Director Okey Stephanie sold $270,000 worth of shares (5,000 units at $54.00), decreasing direct ownership by 36% to 8,867 units (SEC Form 4) - Quantisnow
PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
GC Wealth Management RIA LLC Purchases Shares of 8,032 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):